To explore the efficacy of lorlatinib/lorlatinib in the treatment of bone metastasis

Lorlatinib, also known as lorlatinib ( Lorlatinib), is a cutting-edge third-generation oral tyrosine kinase inhibitor that specifically targets anaplastic lymphoma kinase (ALK). Studies at the cellular level have confirmed that lorlatinib exhibits higher efficacy than second-generation inhibitors and has a broader ability to respond to drug-resistant mutants of ALK. For patients who have developed resistance to other ALK inhibitors (whether first-generation, second-generation, or both), lorlatinib can still show significant anti-tumor effects. It is worth mentioning that it also shows excellent activity in the brain of patients with central nervous system metastasis, especially leptomeningeal metastasis.

Metastasis of lung cancer is one of its malignant characteristics. At the time of diagnosis, approximately 20% to 50% of patients with non-small cell lung cancer have metastasized. The most common sites of distant metastasis include the brain (10%), bone (7%), and liver (5%). In addition, skeletal muscle is also a possible metastasis site of non-small cell lung cancer, and it mostly occurs in the trunk or upper limbs. Global phase 2 clinical trial results show that lorlatinib has a therapeutic effect on patients with EML4-ALK-positive lung cancer who have previously been treated with previous-generation ALK inhibitors such as alectinib or crizotinib.

The data report pointed out that nearly half (47%) of patients who had previously received at least one ALK inhibitor treatment had their symptoms improved after using lorlatinib. Their median progression-free survival (PFS) was extended to 6.9 months, and the median time to first tumor response was only 1.4 months. Such rapid response times and high response rates may have important implications for patients with painful skeletal muscle metastases (SMM). However, these positive results still need to be further verified and supported by larger studies.